US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Maze Therapeutics / Equity Capital Markets

<ul>
<li>The company priced 8.75 million shares at $16.00, upsized from its original filing, and opened at $16.12—a 0.8% premium at first trade.</li>
<li>Amid broad biotech sector volatility and light volume, MAZE dropped to a low of $6.71 in April but has since rebounded closer to the IPO price. </li>
<li>For Maze, the next chapter will be shaped by clinical data with readouts expected later this year and in the first quarter of 2026. </li>
</ul>


The company priced 8.75 million shares at $16.00, upsized from its original filing, and opened at $16.12—a 0.8% premium at first trade.
Amid broad biotech sector volatility and light volume, MAZE dropped to a low of $6.71 in April but has since rebounded closer to the IPO price. 
For Maze, the next chapter will be shaped by clinical data with readouts expected later this year and in the first quarter of 2026. 


Maze Therapeutics (MAZE) Six Month Summary: A Volatile Debut with High-Stakes Catalysts Ahead

<ul>
<li>
<a href="https://www.smartkarma.com/entities/maze-therapeutics-inc" target="_blank" data-smartkarma-citation="entities:44247:1" rel="noopener">Maze Therapeutics (MAZE US)</a> upsized its transaction but saw its IPO price dip below issue on day one.</li>
<li>A critical piece of information, price guidance, was missing from the final channel check sending a warning message to the market.</li>
<li>With the lack of enthusiasm for this IPO during its first session, we would encourage investors to exercise caution on this IPO in the aftermarket.</li>
</ul>



Maze Therapeutics (MAZE US) upsized its transaction but saw its IPO price dip below issue on day one.
A critical piece of information, price guidance, was missing from the final channel check sending a warning message to the market.
With the lack of enthusiasm for this IPO during its first session, we would encourage investors to exercise caution on this IPO in the aftermarket.


Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

<ul>
<li>The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. </li>
<li>According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.</li>
<li>Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.</li>
</ul>


The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. 
According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.
Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.


Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

<ul>
<li>The company has a potential blockbuster treatment for a certain type of chronic kidney disease  affecting millions of Americans.</li>
<li>The company could raise up to $132.6m if priced at the high-end of the range which would value the company at $728m.</li>
<li>The sector vastly underperformed in the aftermarket and is looking to start 2025 on the right foot.</li>
</ul>


The company has a potential blockbuster treatment for a certain type of chronic kidney disease  affecting millions of Americans.
The company could raise up to $132.6m if priced at the high-end of the range which would value the company at $728m.
The sector vastly underperformed in the aftermarket and is looking to start 2025 on the right foot.


Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

<ul>
<li>Currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease</li>
<li>Lead candidate initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose their first patient in the first quarter of 2025</li>
<li>We anticipate this company to set terms (share size, price range) in the next week for a late January / early February debut.</li>
</ul>


Currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease
Lead candidate initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose their first patient in the first quarter of 2025
We anticipate this company to set terms (share size, price range) in the next week for a late January / early February debut.


Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

United States

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic diseases, including obesity.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Maze Therapeutics (MAZE US)

Maze Therapeutics (MAZE) Six Month Summary: A Volatile Debut with High-Stakes Catalysts Ahead

Maze prices upsized IPO, opens at slight premium but has traded below issue for the majority of its life as a public company; future hinges on...

IPO Boutique

Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

Maze Therapeutics upsizes IPO but sees price dip below issue on day one, lack of price guidance sends warning message to market, caution advised...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Maze Therapeutics (MAZE) Six Month Summary: A Volatile Debut with High-Stakes Catalysts Ahead

​Maze prices upsized IPO, opens at slight premium but has traded below issue for the majority of its life as a public company; future hinges on...

IPO Boutique

Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

​Maze Therapeutics upsizes IPO but sees price dip below issue on day one, lack of price guidance sends warning message to market, caution advised...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

​Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

​Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

IPO Boutique

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

​A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut...

IPO Boutique

Maze prices upsized IPO, opens at slight premium but has traded below issue for the majority of its life as a public company; future hinges on...

Maze Therapeutics upsizes IPO but sees price dip below issue on day one, lack of price guidance sends warning message to market, caution advised...

Biotech company gains momentum with sector investors during oversubscribed four-day roadshow. IPO Boutique provides a forecast for the upcoming...

Company with potential blockbuster treatment for chronic kidney disease aims to raise $132.6m, looking to bounce back after underperforming...

A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut...